Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of morning or bedtime dosing of the valsartan/amlodipine on nocturnal blood pressure and target organ protection in patients with hypertension

Trial Profile

Effects of morning or bedtime dosing of the valsartan/amlodipine on nocturnal blood pressure and target organ protection in patients with hypertension

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 30 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amlodipine/valsartan (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Acronyms CPET
  • Most Recent Events

    • 30 May 2018 Results of a sub-analysis assessing the association of changes in Brachial/central nocturnal SBP with change in urine albumin-creatinine ratio, published in the American Journal of Hypertension
    • 26 Oct 2015 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan record.
    • 29 Sep 2015 Planned End Date changed from 30 Sep 2015 to 14 Aug 2015, as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top